Invesco S&P 500 Low Volatility ETF (SPLV) Stock Price Today
Aura AI Summary
Key Stats
- $7.11BMarket Cap
- 2,304,738Volume
- -Sector
- $77.9752W High
- $70.3052W Low
- 125 DaysTypical Hold Time
- -Enterprise Value
- -Div Yield
- -Trading Activity
Track Invesco S&P 500 Low Volatility ETF (SPLV) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Invesco S&P 500 Low Volatility ETF has traded between a low of $70.3 and a high of $77.97, highlighting its annual price range. Buy and sell Invesco S&P 500 Low Volatility ETF shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Most Recent News
Kingfisher Mining raises $2.25M to boost Copper Blow copper-gold exploration near Broken Hill.
Kingfisher Mining secured $2.25 million through a share placement at a 5.6% premium to fund expanded drilling and exploration at its Copper Blow Project near Broken Hill. Recent drilling showed promising copper-gold grades, with significant untested ...

Disc Medicine to webcast APOLLO Phase 3 trial results of bitopertin for erythropoietic protoporphyria
Disc Medicine announced a webcast on October 19, 2026, to discuss topline results from its APOLLO Phase 3 trial of bitopertin, an investigational oral drug for erythropoietic protoporphyria (EPP). Bitopertin targets glycine transporter 1 to modulate ...

Actinogen Medical nears key Alzheimer's trial results with strong cash position of A$21.9M.
Actinogen Medical completed the main phase of its XanaMIA Phase 2b/3 Alzheimer's trial, with topline results expected in November. The trial tests Xanamem 10 mg daily in mild to moderate Alzheimer's patients, focusing on cognitive outcomes. The compa...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.